グレード
pharmaceutical primary standard
APIファミリー
dextropropoxyphene
メーカー／製品名
EDQM
薬剤管理
regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
保管温度
2-8°C
InChI
1S/C22H29NO2.ClH/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;/h6-15,18H,5,16-17H2,1-4H3;1H/t18-,22+;/m1./s1
InChI Key
QMQBBUPJKANITL-MYXGOWFTSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
アプリケーション
Dextropropoxyphene for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
その他情報
Sales restrictions may apply.
シグナルワード
Danger
危険有害性情報
危険有害性の分類
Acute Tox. 3 Oral
保管分類コード
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
最新バージョンのいずれかを選択してください：
Wayne A Ray et al.
Pharmacoepidemiology and drug safety, 22(4), 403-412 (2013-02-15)
The opioid analgesic propoxyphene was withdrawn from the US market in 2010, motivated by concerns regarding fatality in overdose and adverse cardiac effects, including prolongation of the QT interval. These concerns were based on case reports, summary vital statistics, and
India urged to reverse dextropropoxyphene ban.
Dinesh C Sharma
The Lancet. Oncology, 14(9), e344-e344 (2013-09-24)
P Bertin et al.
The journal of nutrition, health & aging, 17(8), 681-686 (2013-10-08)
The main objective of the S.AGES (Elderly Subjects) cohort study is to describe the current therapeutic strategy for chronic pain in non-institutionalised elderly patients in France. In this prospective cohort study, non-institutionalised patients aged 65 years and over with chronic
Nick A Buckley et al.
The Medical journal of Australia, 199(4), 257-260 (2013-08-30)
• The Therapeutic Goods Administration determined in November 2011 that dextropropoxyphene should be removed from the Australian Register of Therapeutic Goods. This is consistent with this drug's removal from the market in many other developed countries. • However, dextropropoxyphene is
Suicides involving co-proxamol fell dramatically after withdrawal in UK.
Zosia Kmietowicz
BMJ (Clinical research ed.), 344, e3255-e3255 (2012-05-11)
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）